Can a diabetes drug boost heart function in obese patients?

NCT ID NCT06782139

Recruiting now Disease control Sponsor: Korea University Anam Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether enavogliflozin, a diabetes drug, can improve heart function and exercise capacity in 30 obese adults with type 2 diabetes. Participants receive either the drug or a placebo for 12 weeks, and doctors measure changes in heart blood flow and fitness. The goal is to see if the drug helps the heart work better in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enavogliflozin (a drug that lowers blood sugar and may help the heart)
What this could lead to: If it works, this could show that enavogliflozin improves heart function and exercise ability in people with obesity and diabetes.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drug may not show clear benefits over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND TYPE 2 DIABETES

Contacts and locations

Locations

Korea University Anam Hospital
RECRUITING

Seoul, 02841, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.